Limits...
Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.

Remuzgo-Martínez S, Genre F, López-Mejías R, Ubilla B, Mijares V, Pina T, Corrales A, Blanco R, Martín J, Llorca J, González-Gay MA - Sci Rep (2016)

Bottom Line: Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033).Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016).Our study supports an important role of OPG and TRAIL in RA.

View Article: PubMed Central - PubMed

Affiliation: Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

ABSTRACT
Osteoprotegerin (OPG), receptor activator of nuclear factor-ΚB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been involved in rheumatoid arthritis (RA) pathophysiology. In this study, we assessed messenger RNA (mRNA) expression of these molecules by qPCR in peripheral blood from 26 patients with RA (12 of them with ischemic heart disease -IHD) and 10 healthy controls. Correlation coefficients between OPG, RANKL and TRAIL expression levels in RA patients and their clinical and demographic characteristics were also evaluated. Whereas OPG and OPG/TRAIL ratio expression were significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033). Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016). Our study supports an important role of OPG and TRAIL in RA. Furthermore, it highlights an effect of biologic DMARDs in the modulation of RANKL.

No MeSH data available.


Related in: MedlinePlus

Increased OPG mRNA expression in patients with RA and TRAIL mRNA expression in RA patients with IHD.OPG and TRAIL expression was normalized to two housekeeping genes (beta-actin and GAPDH). (a) Differential expression of relative OPG mRNA was analyzed between control group (n = 10) and RA patients (n = 26). (b) Differential expression of relative TRAIL mRNA was analyzed between RA patients stratified according to the presence (n = 12) or absence of IHD (n = 14). Each bar represents mean value ± SD obtained for each sample in triplicate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940734&req=5

f1: Increased OPG mRNA expression in patients with RA and TRAIL mRNA expression in RA patients with IHD.OPG and TRAIL expression was normalized to two housekeeping genes (beta-actin and GAPDH). (a) Differential expression of relative OPG mRNA was analyzed between control group (n = 10) and RA patients (n = 26). (b) Differential expression of relative TRAIL mRNA was analyzed between RA patients stratified according to the presence (n = 12) or absence of IHD (n = 14). Each bar represents mean value ± SD obtained for each sample in triplicate.

Mentions: Expression of the OPG gene was significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013, Table 1). In this regard, patients with RA had a mean OPG expression of 6.68 ± 3.69 whereas controls had a mean OPG expression of 3.74 ± 2.00 (Table 1 and Fig. 1a). However, no significant differences were found between patients and controls in RANKL and TRAIL mRNA expression (Table 1). A decreased RANKL/OPG ratio and an increased OPG/TRAIL ratio was observed in patients compared to controls (fold change = 0.50 and 2.07, respectively). These differences in expression were statistically significant (p = 0.020 and p = 0.030, respectively, Table 1).


Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.

Remuzgo-Martínez S, Genre F, López-Mejías R, Ubilla B, Mijares V, Pina T, Corrales A, Blanco R, Martín J, Llorca J, González-Gay MA - Sci Rep (2016)

Increased OPG mRNA expression in patients with RA and TRAIL mRNA expression in RA patients with IHD.OPG and TRAIL expression was normalized to two housekeeping genes (beta-actin and GAPDH). (a) Differential expression of relative OPG mRNA was analyzed between control group (n = 10) and RA patients (n = 26). (b) Differential expression of relative TRAIL mRNA was analyzed between RA patients stratified according to the presence (n = 12) or absence of IHD (n = 14). Each bar represents mean value ± SD obtained for each sample in triplicate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940734&req=5

f1: Increased OPG mRNA expression in patients with RA and TRAIL mRNA expression in RA patients with IHD.OPG and TRAIL expression was normalized to two housekeeping genes (beta-actin and GAPDH). (a) Differential expression of relative OPG mRNA was analyzed between control group (n = 10) and RA patients (n = 26). (b) Differential expression of relative TRAIL mRNA was analyzed between RA patients stratified according to the presence (n = 12) or absence of IHD (n = 14). Each bar represents mean value ± SD obtained for each sample in triplicate.
Mentions: Expression of the OPG gene was significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013, Table 1). In this regard, patients with RA had a mean OPG expression of 6.68 ± 3.69 whereas controls had a mean OPG expression of 3.74 ± 2.00 (Table 1 and Fig. 1a). However, no significant differences were found between patients and controls in RANKL and TRAIL mRNA expression (Table 1). A decreased RANKL/OPG ratio and an increased OPG/TRAIL ratio was observed in patients compared to controls (fold change = 0.50 and 2.07, respectively). These differences in expression were statistically significant (p = 0.020 and p = 0.030, respectively, Table 1).

Bottom Line: Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033).Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016).Our study supports an important role of OPG and TRAIL in RA.

View Article: PubMed Central - PubMed

Affiliation: Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

ABSTRACT
Osteoprotegerin (OPG), receptor activator of nuclear factor-ΚB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been involved in rheumatoid arthritis (RA) pathophysiology. In this study, we assessed messenger RNA (mRNA) expression of these molecules by qPCR in peripheral blood from 26 patients with RA (12 of them with ischemic heart disease -IHD) and 10 healthy controls. Correlation coefficients between OPG, RANKL and TRAIL expression levels in RA patients and their clinical and demographic characteristics were also evaluated. Whereas OPG and OPG/TRAIL ratio expression were significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033). Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016). Our study supports an important role of OPG and TRAIL in RA. Furthermore, it highlights an effect of biologic DMARDs in the modulation of RANKL.

No MeSH data available.


Related in: MedlinePlus